GSK nets £1.2bn after selling final stake in Sensodyne maker Haleon
The IndependentFor free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy GSK has raised £1.2 billion after offloading its last remaining stake in Sensodyne and Advil firm Haleon, nearly two years after spinning off the consumer healthcare firm. GSK's exit of its position in Haleon is consistent with its previous commitments to monetise its holding in a disciplined manner GSK GSK said: “Following settlement of the placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon. Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer, sitting as a joint venture within GSK. Haleon also agreed a deal in January to offload its ChapStick lip balm brand to private equity-owned Suave Brands Company in a deal worth around 510 million US dollars, while it has sold off athlete’s foot treatment Lamisil last year.
History of this topic
GSK offloads £800m stake in healthcare spin-off Haleon
The IndependentDiscover Related
)
)
)
)
)
)
